Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03352323 · ClinicalTrials.gov registry record · Phase 3
An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
A Phase 3 study, sponsored by Padagis.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT03352323 is a Phase 3 study that has completed, run by Padagis. The registered enrollment target is 50 participants.
The verdict
NCT03352323, a Phase 3 study, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
the study will measure the decrease in redness on the face of rosacea subjects
Interventions
- DRUG Oxymetazoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-10-18 |
| Est. Completion | 2018-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03352323
The ClinicalTrials.gov registry entry for NCT03352323 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Padagis, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxymetazoline is the first listed.
NCT03352323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03352323 about?
NCT03352323 is a clinical study titled "An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea". the study will measure the decrease in redness on the face of rosacea subjects
What is the current status of trial NCT03352323?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2017-10-18. Estimated completion is 2018-03-30.
What interventions are being tested in trial NCT03352323?
The interventions under investigation include: Oxymetazoline (DRUG).
Who is sponsoring clinical trial NCT03352323?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.